Acadia's FDA Breakthrough Designation For Pimavanserin Draws Mixed Response

By: via Benzinga
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stock initially jumped above $41 per share on Thursday after the FDA granted Breakthrough ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.